EBOS Group Ltd (EBO):企業の財務・戦略的SWOT分析

◆英語タイトル:EBOS Group Ltd (EBO) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C7717
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

EBOS Group Ltd (EBO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and medical device suppliers. The company offers products under various brands such as Symbion, Pro Pharma, Minfosa, Master Pet, Vita Pet, Black Hawk and Faulding among others. EBOS serves private and public hospitals, general practitioners, aged care facilities, community centers, pharmacies, professionals, consumers, pet stores, veterinary clinics and manufacturers. It has operational presence in Australia and New Zealand. EBOS is headquartered in Docklands, Victoria, Australia.

EBOS Group Ltd Key Recent Developments

Aug 23,2018: EBOS delivers record 2018 earnings
Jul 02,2018: EBOS Group achieves Australian pharmaceutical distribution deal
Jul 02,2018: EBOS wins Chemist Warehouse tender to supply pharmaceuticals
Feb 21,2018: EBOS delivers record first-half earnings
Dec 13,2017: EBOS Group announces its next CEO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
EBOS Group Ltd – Key Facts 6
EBOS Group Ltd – Key Employees 7
EBOS Group Ltd – Key Employee Biographies 8
EBOS Group Ltd – Key Operational Employees 9
EBOS Group Ltd – Major Products and Services 10
EBOS Group Ltd – History 11
EBOS Group Ltd – Company Statement 13
EBOS Group Ltd – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 17
Company Overview 17
EBOS Group Ltd – Business Description 18
Business Segment: Animal Care 18
Overview 18
Performance 18
Business Segment: Healthcare 18
Overview 18
Performance 18
Geographical Segment: Australia 18
Performance 18
Geographical Segment: New Zealand 18
Performance 18
EBOS Group Ltd – Corporate Strategy 19
EBOS Group Ltd – SWOT Analysis 20
SWOT Analysis – Overview 20
EBOS Group Ltd – Strengths 20
EBOS Group Ltd – Weaknesses 21
EBOS Group Ltd – Opportunities 22
EBOS Group Ltd – Threats 23
EBOS Group Ltd – Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios – Capital Market Ratios 25
Financial Ratios – Annual Ratios 26
Performance Chart 29
Financial Performance 29
Financial Ratios – Interim Ratios 30
Financial Ratios – Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
EBOS Group Ltd, Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Aug 23, 2018: EBOS delivers record 2018 earnings 35
Jul 02, 2018: EBOS Group achieves Australian pharmaceutical distribution deal 36
Jul 02, 2018: EBOS Group achieves Australian pharmaceutical distribution deal 37
Jul 02, 2018: EBOS wins Chemist Warehouse tender to supply pharmaceuticals 38
Feb 21, 2018: EBOS delivers record first-half earnings 39
Dec 13, 2017: EBOS Group announces its next CEO 41
Aug 24, 2017: EBOS reports record earnings for 2017 42
Feb 22, 2017: EBOS Group Announces Strong first half delivers double-digit revenue and profit growth 44
Jan 17, 2017: Ebos Group Change Of Registered Office In Australia 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
EBOS Group Ltd, Key Facts 6
EBOS Group Ltd, Key Employees 7
EBOS Group Ltd, Key Employee Biographies 8
EBOS Group Ltd, Key Operational Employees 9
EBOS Group Ltd, Major Products and Services 10
EBOS Group Ltd, History 11
EBOS Group Ltd, Other Locations 15
EBOS Group Ltd, Subsidiaries 15
EBOS Group Ltd, Key Competitors 24
EBOS Group Ltd, Ratios based on current share price 25
EBOS Group Ltd, Annual Ratios 26
EBOS Group Ltd, Annual Ratios (Cont...1) 27
EBOS Group Ltd, Annual Ratios (Cont...2) 28
EBOS Group Ltd, Interim Ratios 30
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
EBOS Group Ltd, Recent Deals Summary 34
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
EBOS Group Ltd, Performance Chart (2014 - 2018) 29
EBOS Group Ltd, Ratio Charts 31
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 33

★海外企業調査レポート[EBOS Group Ltd (EBO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Austrian Post:企業の戦略・SWOT・財務情報
    Austrian Post - Strategy, SWOT and Corporate Finance Report Summary Austrian Post - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Marafiq:企業の発電所・SWOT分析2018
    Marafiq - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives …
  • Merck & Co Inc (MRK)-製薬・医療分野:企業M&A・提携分析
    Summary Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respirato …
  • Beckman Coulter Inc:企業の戦略的SWOT分析
    Beckman Coulter Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • University College London Hospitals NHS Foundation Trust:企業の戦略的SWOT分析
    University College London Hospitals NHS Foundation Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key …
  • Gubre Fabrikalari TAS (GUBRF):企業の財務・戦略的SWOT分析
    Summary Gubre Fabrikalari TAS (Gubre Fabrikalari) is a chemical company that manufactures and markets chemical fertilizers. The company offers solid products, liquid products, powder products, organic products and special products. Its special products include humic acid, starwet, gibbest, dengem, a …
  • Ono Pharmaceutical Co Ltd (4528):企業の財務・戦略的SWOT分析
    Ono Pharmaceutical Co Ltd (4528) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Fractyl Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fractyl Laboratories Inc (Fractyl) is a clinical-stage medical technology company that develops novel devices and procedures to overcome insulin resistance and restitute metabolic health. The company developed a device-based clinical platform to change the way of treating metabolic diseases. …
  • The Pep Boys – Manny, Moe & Jack of California:企業の戦略的SWOT分析
    The Pep Boys - Manny, Moe & Jack of California - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Mersana Therapeutics Inc (MRSN):製薬・医療:M&Aディール及び事業提携情報
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes F …
  • Dicerna Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Dicerna Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dicerna Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Morepen Laboratories Ltd (MOREPENLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Morepen Laboratories Ltd (Morepen Laboratories) is a manufacturer and supplier of active pharma ingredients and formulations. The company offers active pharma ingredients, formulation and homehealth solutions. It offers products in forms of tablets, capsules, liquids and powders. Morepen Lab …
  • Korea Electric Power Corporation (015760):企業の財務・戦略的SWOT分析
    Korea Electric Power Corporation (015760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Medistim ASA (MEDI):企業の財務・戦略的SWOT分析
    Summary MediStim ASA (MediStim) is a medical device company that manufactures and markets medical products for cardiac, vascular and transplant surgeries. The company’s products include MiraQ cardiac, MiraQ vascular, MiraQ ultimate system, imaging probes, flow probes, VeriQ C and VeriQ systems. Its …
  • Arena Pharmaceuticals Inc (ARNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. It is evaluating its lead candidate etrasimod for multiple inflammatory indications including ulcerative colitis, primary biliary chol …
  • Langley Holdings plc:企業の戦略・SWOT・財務分析
    Langley Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Langley Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Cathay Pacific Airways Limited:企業のM&A・事業提携・投資動向
    Cathay Pacific Airways Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cathay Pacific Airways Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Nuo Therapeutics Inc (AURX):医療機器:M&Aディール及び事業提携情報
    Summary Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. T …
  • Seven & i Holdings Co., Ltd. (3382):企業の財務・戦略的SWOT分析
    Seven & i Holdings Co., Ltd. (3382) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Marafiq:企業の戦略的SWOT分析
    Marafiq - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆